risks of capillary collection are less than that with venipuncture.
Hemoglobin interferes with determination of total bilirubin by the diazo procedixe with the DuPont aca. We compared results by that procedure with those by a manual direct spectrophotometric two-wavelength method. Because the manual method was not inhibited by hemolysis as was the DuPont aca diazo procedure, we reprogrammed our DuPont aca to measure the absorbance of diluted serum samples at 452 and 577 nm with use of DuPont absorbance packs as the sample pack and cuvette. Results correlated well with those by the manual spectrophotometric method, and hemolysis no longer interfered. The method is primarily intended for use with serum from neonates.
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With the DuPont aca discrete analyzer, total bilirubin is determined by a modified diazo procedure (1) with the surfactant Tween-20 being used to solubilize unconjugated bilirubin. Blijenberg et al. (2) found that the degree of interference by hemoglobin in the aca bilirubin method was unacceptable, but became constant at high hemoglobin concentrations in plasma. Their solution was to construct a new Regional Laboratory, Dr. Everett Chalmers Hospital, Fredericton, New Brunswick, Canada E3B 5N5.
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calibration graph after adding hemoglobin to the buffer diiuent to give a final concentration of about 2.42 g of hemoglobin per liter in the test pack.
We believed that a better approach for neonatal samples would be to determine bilirubin directly, with the aca being used as a spectrophotometer for determining bilirubin on the basis of its differential absorbance at 452 and 577 nm. Blank absorbance packs were used as the sample carrier in our procedure. The results correlated well with those by the corresponding manual two-wavelength procedure. The new procedure requires less sample than does the diazo method used in the aca and it is not affected by hemolysis.
Materials and Methods

Instrumentation
We used a Model PM2DL spectrophotometer (Carl Zeiss Canada Ltd., Montreal, Quebec) for the manual bilirubin determination.
A 20-itL serum sample was diluted with 2.0 mL of phosphate buffer and the absorbance measured at 450 and 575 nm as originally described by White et al. (3) Total bilirubin was measured with an aca II (DuPont Co., Instrument Products, Automatic Clinical Analysis Division, Wilmington, DE 19898). We evaluated their diazo procedure (1) and also used their absorbance packs in our two-wavelength direct method adapted to the aca. The following changes were considered optimal for our method: Buffer in position 6, sample volume 40 zL, filter number 5-452 nm, filter number 10-577 nm, theoretical scale factor 0.1803, theoretical starting point 000.0 The letter wheels were programmed to print PTBIL (pediatric total bilirubin), second decimal position. DuPont absorbance packs were used in our method with the black bar in the first position removed (method code 62). 
Reagents and Procedures
The reference serum we used was "Versatol Pediatric Reference Serum" (General Diagnostics, Scarborough, Ontario).
Sample Collection
All plasma samples were collected by heel prick, into Dade Natelson Blood Collecting Tubes with ammonium heparin as anticoagulant (Canadian Laboratory Supplies, Dartmouth,
N.S.).
Results
Linearity.
We evaluated the linearity of the direct PTBIL procedure by use of eight standard bilirubin solutions, in concentrations ranging from 50 to 400 mg/L, in 50-mg/L increments. The upper limit of linearity for bilirubin was 300 mg/L.
Precision.
The results are shown in Table 1 .
Analytical recovery.
For the PTBIL method, bilirubin recovery was evaluated by assaying solutions of pure bilirubin in pooled serum. Solutions with five different bilirubin concentrations were obtained by diluting the 300 mg/L standard solution. In this manner we assayed six samples, with concentrations ranging from 50-300 mg/L. The mean percentage recovery was 93% (range 92-94%).
Interferences.
Because hemoglobin has been shown to inhibit diazo procedures for bilirubin, and because hemolyzed samples are commonplace when blood is collected from neonates by capillary tubes, we studied the effect of hemolysis on our bilirubin method(s). Control serum was supplemented with hemoglobin to give five concentrations, 250 to 2000 mgTL. Figure 1 shows the inhibitory effect of hemoglobin, even at 250 mg/L, on the DuPont aca diazo procedure. In contrast, inhibition by hemoglobin was not considered significant for the manual and PTBIL differential spectrophotometric methods.
Split -sample comparison.
Plasma samples were analyzed by the manual two-wavelength method and by our modified aca method, simultaneously, to avoid any errors caused by the 
Discussion
The manufacturer and others (2) caution the operator of the aca about using the DuPont diazo procedure when neonatal samples are to be analyzed for bilirubin. Blijenberg et al. (2) measured hemoglobin in 159 neonatalspecimensand reported an average hemoglobin concentration of 1700 mg/L. From Figure 1 ore can see that this would correspond to about a 25% decrease in the value for apparent bilirubin. One could use, with some validity, the DuPont diazo procedure to determine bilirubin in the serum of neonates if the hemoglobin concentration was <400 mg/L, but some other procedure not subject to hemoglobin interference would be more appropriate.
Results by the manual differential spectrophotometric procedure and our adaption of it to the aca correlate well; they are unaffected by the concentrations of hemoglobin commonly found in neonatal samples (6) . That the accuracy of our method was good was indicated by the average recovery exceeding 93%. The limits of linearity (300 mg/L) were acceptable, because the method is only intended for use with samples from neonates.
Lipemia may interfere in our method for bilirubin, but li-pemia is not a problem with most samples from neonates, so this interference was not well investigated. The manufacturer has informed us since our work was completed that they intend to introduce a "neonatal bilirubin" procedure for the aca. The price for the DuPont pediatric test pack is 12% higher than that of absorbance packs we used in our procedure. The saving would be significant with our volume of neonatal bilirubin requests (50-60/week).
We believe that our procedure is reliable for measuring bilirubin in serum of neonates. The method is worthy of consideration by aca users who have to quantitate neonatal samples for bilirubin and do not have a commercial bilirubinometer in their laboratory.
In conclusion, we believe that our work on bilirubin demonstrates the feasibility of users making improvements on the aca to meet the needs of their laboratory.
CLIN. CHEM. 25/10, 1841-1843 (1979) 
